Iksuda Therapeutics Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
43
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$18.2M
- Investors
-
9
Iksuda Therapeutics General Information
Description
Developer of biological therapeutics designed to target difficult-to-treat cancers, including those resistant or refractory to current therapies. The company's therapeutics are antibody-drug conjugates that help in the treatment of cancer as well as tumor and tumor subtypes through careful selection of the right combinations of payload, linker, and conjugation chemistry, enabling patients to receive treatment for cancer.
Contact Information
Website
www.iksuda.comCorporate Office
- The Biosphere, Draymans Way
- Newcastle Helix
- Newcastle upon Tyne NE4 5BX
- England, United Kingdom
Corporate Office
- The Biosphere, Draymans Way
- Newcastle Helix
- Newcastle upon Tyne NE4 5BX
- England, United Kingdom
Iksuda Therapeutics Timeline
Iksuda Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 30-Jun-2025 | $18.2M | Completed | Clinical Trials - Phase 1 | ||
| 6. Later Stage VC (Series A) | 25-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 27-Jul-2015 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 15-Jul-2013 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 21-Jun-2012 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 09-Oct-2010 | $1.73M | $1.73M | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 21-Nov-2007 | Completed | Startup |
Iksuda Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A Preferred | ||||||||
| Series A | ||||||||
| Series A NV | ||||||||
| Series A Preferred | ||||||||
| Series A Preferred | ||||||||
| Series A Preferred | ||||||||
| A Ordinary | 79,894 | $0.001000 | $7.51 | $7.51 | 1x | $7.51 | 1% | |
| Ordinary | 18,642 | $0.001000 | $7.51 | $7.51 | 1x | $7.51 | 0.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Iksuda Therapeutics Comparisons
Industry
Financing
Details
Iksuda Therapeutics Competitors (43)
One of Iksuda Therapeutics’s 43 competitors is CimCure, a Venture Capital-Backed company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CimCure | Venture Capital-Backed | Amsterdam, Netherlands | ||||
| Immunophotonics | Private Equity-Backed | Saint Louis, MO | ||||
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| XBiotech | Corporation | Austin, TX | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Iksuda Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Iksuda Therapeutics Patents
Iksuda Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202510179-D0 | Antibody conjugate | Pending | 25-Jun-2025 | ||
| GB-202416493-D0 | Antibody conjugates | Pending | 08-Nov-2024 | ||
| WO-2026093752-A1 | Antibody conjugates targeting b7-h3 | Pending | 30-Oct-2024 | ||
| WO-2026087903-A1 | Antibodies conjugated to cyclopropylbenzoindole dimer drug moieties, and methods of use and treatment | Pending | 25-Oct-2024 | ||
| GB-202415789-D0 | Antibody-drug conjugate compounds, and methods of use and treatment | Pending | 25-Oct-2024 | A61K47/6803 |
Iksuda Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Iksuda Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| LigaChem Biosciences | Corporation | Minority | ||
| Celltrion | Corporation | Minority | ||
| IP | Corporation | Minority | ||
| Mirae Asset Capital | Venture Capital | Minority | ||
| North East Finance | Venture Capital | Minority |
Iksuda Therapeutics FAQs
-
When was Iksuda Therapeutics founded?
Iksuda Therapeutics was founded in 2007.
-
Where is Iksuda Therapeutics headquartered?
Iksuda Therapeutics is headquartered in Newcastle upon Tyne, United Kingdom.
-
What is the size of Iksuda Therapeutics?
Iksuda Therapeutics has 43 total employees.
-
What industry is Iksuda Therapeutics in?
Iksuda Therapeutics’s primary industry is Drug Discovery.
-
Is Iksuda Therapeutics a private or public company?
Iksuda Therapeutics is a Private company.
-
What is the current valuation of Iksuda Therapeutics?
The current valuation of Iksuda Therapeutics is .
-
What is Iksuda Therapeutics’s current revenue?
The current revenue for Iksuda Therapeutics is .
-
How much funding has Iksuda Therapeutics raised over time?
Iksuda Therapeutics has raised $77.2M.
-
Who are Iksuda Therapeutics’s investors?
LigaChem Biosciences, Celltrion, IP, Mirae Asset Capital, and North East Finance are 5 of 9 investors who have invested in Iksuda Therapeutics.
-
Who are Iksuda Therapeutics’s competitors?
CimCure, Immunophotonics, Meditope Biosciences, XBiotech, and Rein Therapeutics are some of the 43 competitors of Iksuda Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
